Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFOX-6 in metastatic colorectal cancer after adjuvant oxaliplatin
NCT00988897Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Oct 2009
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), sponsored by Sanofi. Primary endpoint: Disease Control Rate at 16 weeks. Planned start Oct 2009; status: withdrawn.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00988897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00988897.